Latest: Watch here for details of new products and services.
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Comparison
- Forums
- Visit our forums
- Jobs
- Visit our job site
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire New!
- Contact us
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
Cellophil (TM) is particularly designed for optical lenses, drug delivery and also may be used as additive for food and cosmetics or as fiber for fabrics. More
Surgical implant for treatment and prevention of post-operative infections More
Researchers at the University of Western Ontario have developed a Pulmonary Drug Delivery Technology Suite comprised of two innovative inventions for the precision measurement and dispensing of micro fine, dry powders. More
Coupling drug substances with hydroxyethyl starch (HES) derivatives to improve pharmacokinetics and pharmacodynamics. More
This invention relates to a computer-controlled physiological flow simulator for use in the study of vascular hemodynamics and the calibration of clinical imaging systems used to measure blood flow More
his invention concerns a system and method of obtaining four-dimensional (4-D) ultrasound images of moving tissue such as the human heart or lungs, where time is the fourth dimension. More
Use of depth filters to remove prion infectivity from plasma - derived therapeutic products and/or other biologics. Depth Filtration is a chemically inactive process and therefore does not introduce potentially toxic bi-products or alter components. More
Western inventors have identified a group of 12 differentially expressed proteins in Preeclampsia (PE) patients using a state-of-art proteomics based approach. More
Proprietary manufacturing process for a liquid IVIgG product - in great demand world-wide as one of the principal therapeutics obtained from blood plasma. Process delivers a low IgA content, which increases renal tolerability. More
Proprietary process to produce a freeze-dried fibrinogen therapeutic product, easily soluble. Includes two virus inactivation processes: dry heat treatment and solvent/detergent. More
Your selection
Browse By
- Industry sector
- Therapeutic device
- Therapeutic medical equipment
- Vision Care
- Therapeutic target
- Acute coronary syndromes
- Anemia
- Anticoagulants
- Blood clotting
- Blood composition
- Cardiovascular disorder (other)
- Cerebrovascular disorders
- Thrombotic disorders
- Treatments
- Vascular
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us